Patents Represented by Attorney Richard Aron Osman
-
Patent number: 6821736Abstract: The invention provides methods and compositions relating to novel human cellular inhibitor of apoptosis proteins (c-IAP1/2) comprising a series of defined structural domain repeats and/or a RING finger domain; in particular, at least two of: a particular first domain repeat, a particular second domain repeat, and a particular third domain repeat, and/or a particular RING finger domain. The proteins provide a c-IAP specific function, with preferred proteins being capable of modulating the induction of apoptosis; for example, by binding a human tumor necrosis factor receptor associated factor (TRAF). The compositions include nucleic acids which encode the subject c-IAP and hybridization probes and primers capable of hybridizing with the disclosed c-IAP genes. The invention includes methods of using the subject compositions in therapy, in diagnosis and in the biopharmaceutical industry.Type: GrantFiled: October 12, 2000Date of Patent: November 23, 2004Assignee: Amgen Inc.Inventors: Mike Rothe, David V Goeddel
-
Patent number: 6815450Abstract: Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a resultant promotion of the regenerative growth of the axon is detected.Type: GrantFiled: March 14, 2003Date of Patent: November 9, 2004Assignee: Children's Medical Center CorporationInventors: Zhigang He, Vuk Koprivica, Rajeev Sivasankaran
-
Patent number: 6752996Abstract: The Parapox B2L virus envelope protein is used as an adjuvant to enhance a subject's response to an administered antigen. Both antibody and cellular immune responses can be modified. B2L protein is particularly useful as an adjuvant for poorly immunogenic tumor vaccines and subunit vaccines, such as those useful for preventing and/or treating flu, tuberculosis, respiratory syncytial virus, anthrax and HIV.Type: GrantFiled: April 15, 2003Date of Patent: June 22, 2004Assignee: Board of Regents, The University of Texas SystemInventors: Stephen A. Johnston, Michael J. McGuire
-
Patent number: 6752995Abstract: In the present invention parapox genomes were screened using a novel expression strategy to test genes for dendritic cell recruitment activity. One gene was identified, designated as B2WL, that induces dendritic cell accumulation when expressed in skin. In additional testing a second gene, PP30, was identified that exhibited adjuvant activity in the absence of stimulating dendritic cell accumulation at the site of inoculation. When co-inoculated with an antigen-encoding plasmid, both genes acted as adjuvants in stimulating an antibody response to antigens. Furthermore, nucleic acids encoding the identified B2WL peptide adjuvant enhanced the level of protection against viral infection provided by immunization with an HA-expression plasmid. Thus, novel adjuvants for genetic immunization are identified.Type: GrantFiled: April 15, 2002Date of Patent: June 22, 2004Assignee: Board of Regents, The University of Texas SystemInventors: Stephen A. Johnston, Michael J. McGuire
-
Patent number: 6740507Abstract: Recombinant cells which express a fluorescent holo-phycobiliprotein fusion protein and methods of use are described. The cells comprises a bilin, a recombinant bilin reductase, an apo-phycobiliprotein fusion protein precursor of the fusion protein comprising a corresponding apo-phycobiliprotein domain, and a recombinant phycobiliprotein domain-bilin lyase, which components react to form the holo-phycobiliprotein fusion protein. Also described are holo-phycobiliprotein based transcription reporter cells and assays, which cells conditionally express a heterologous-to-the-cell, fluorescent, first holo-phycobiliprotein domain.Type: GrantFiled: July 31, 2001Date of Patent: May 25, 2004Assignee: The Regents of the University of CaliforniaInventors: Alexander N. Glazer, Aaron J. Tooley, Yuping Cai
-
Patent number: 6723329Abstract: The Parapox B2L virus envelope protein is used as an adjuvant to enhance a subject's response to an administered antigen. Both antibody and cellular immune responses can be modified. B2L protein is particularly useful as an adjuvant for poorly immunogenic tumor vaccines and subunit vaccines, such as those useful for preventing and/or treating flu, tuberculosis, respiratory syncytial virus, anthrax and HIV.Type: GrantFiled: April 15, 2003Date of Patent: April 20, 2004Assignee: Board of Regents, The University of Texas SystemInventors: Stephen A. Johnston, Michael J. McGuire
-
Patent number: 6667179Abstract: The invention provides methods and compositions for detecting binding or unbinding of a molecule to a substrate. The molecule comprises a luminophore and the substrate comprises a semiconductor which acts as a luminescence quencher to provide distance-dependent quenching of the luminophore. Binding or unbinding of the molecule, which may be covalent or noncovalent, is detected as a decrease or increase, respectively, of the detectable luminescence of the luminophore.Type: GrantFiled: October 28, 1999Date of Patent: December 23, 2003Assignee: The Board of Trustees of the University of IllinoisInventor: Paul R. Selvin
-
Patent number: 6664266Abstract: Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a resultant promotion of the regenerative growth of the axon is detected.Type: GrantFiled: March 14, 2002Date of Patent: December 16, 2003Assignee: Children's Medical Center CorporationInventors: Zhigang He, Vuk Koprivica, Rajeev Sivasankaran
-
Patent number: 6656963Abstract: The invention provides methods and compositions relating to novel bioactive derivatives of indole-3-carbinol (I3C), including pharmaceuticals comprising a pharmaceutically acceptable excipient and a compound of the general formula: which inhibits tumor cell growth. Methods of inhibiting targeted cell growth include contacting a target cell with a disclosed compound under conditions whereby the growth the target cell is inhibited, and methods for evaluating the growth inhibitory activity of the compounds include contacting a cell with an effective amount of the compound and measuring the CDK6 expression in the cell, wherein a reduction in CDK6 expression correlates with the growth inhibitory activity of the compound.Type: GrantFiled: April 8, 2002Date of Patent: December 2, 2003Assignee: The Regents of the University of CaliforniaInventors: Gary L. Firestone, Leonard F. Bjeldanes, Carolyn M. Cover
-
Patent number: 6653450Abstract: The invention provides recombinant procollagen chains having a natural collagen chain separated from one or two propeptides by one or two non-natural site-specific proteolytic agent (e.g., protease) recognition sites. A wide variety of propeptides and site-specific proteolytic agent recognition sites may be used: the selection of particular site-specific proteolytic agent/recognition site pairs is based on the conformation of the resulting procollagen, the availability of the site-specific proteolytic agent, the compatibility of the proteolysis with production of mature collagen, among other factors. Recombinant collagens chains are produced by contacting the subject recombinant procollagen chains with the appropriate site-specific proteolytic agents. Nucleic acids encoding the subject procollagen chains operably linked to transcription regulatory elements are used in vectors and cells for the production of recombinant collagen.Type: GrantFiled: July 22, 1994Date of Patent: November 25, 2003Assignee: Cohesion Technologies, Inc.Inventors: Richard A. Berg, Paul David Toman, Donald G. Wallace
-
Patent number: 6649376Abstract: The invention provides multifunctional fusion constructs which are rapidly incorporated into a macromolecular structure such as a phycobilisome such that the fusion proteins are separated from one another and unable to self-associate. The invention provides methods and compositions for displaying a functional polypeptide domain on an oligomeric phycobiliprotein, including fusion proteins comprising a functional displayed domain and a functional phycobiliprotein domain incorporated in a functional oligomeric phycobiliprotein. The fusion proteins provide novel specific labeling reagents.Type: GrantFiled: December 21, 1999Date of Patent: November 18, 2003Assignee: The Regents of the University of CaliforniaInventors: Alexander N. Glazer, Yuping Cai
-
Patent number: 6623738Abstract: The invention provides methods and compositions relating to two classes of semaphorin receptors, SR1 and SR2. The polypeptides may be produced recombinantly from transformed host cells from the disclosed SR encoding nucleic acids or purified from human cells. The invention provides isolated SR hybridization probes and primers, capable of specifically hybridizing with the disclosed SR genes. SR-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.Type: GrantFiled: November 12, 1999Date of Patent: September 23, 2003Assignee: The Regents of the University of CaliforniaInventors: Marc Tessier-Lavigne, Zhigang He, Hang Chen
-
Patent number: 6613529Abstract: A method and apparatus is provided for mixing a film of fluid, particularly a film of chemical, biochemical, or biological fluids, undergoing a reaction. The apparatus comprises a means for creating a bubble within the film of fluid, and moving the bubble in the fluid, thereby mixing the fluid.Type: GrantFiled: July 15, 2002Date of Patent: September 2, 2003Assignee: Incyte Genomics Inc.Inventors: Tod Bedilion, Loren Titsworth, Erik Bjeldanes, Douglas Gilliland, Lyle Arnold
-
Patent number: 6608026Abstract: The invention provides methods and compositions for enhancing apoptosis of pathogenic cells. The general method comprises the of contacting the cells with an effective amount of an AV peptoid, wherein the AV peptoid is a peptide comprising AX1, wherein X1 is V, I or L, or a peptide mimetic thereof, which interacts with an Inhibitor of Apoptosis protein (IAP) as measured by IAP binding, procaspase-3 activation or promotion of apoptosis, wherein apoptosis of the pathogenic cells is enhanced. The subject compositions encompass pharmaceutical compositions comprising a therapeutically effective amount of a subject AV peptoid in dosage form and a pharmaceutically acceptable carrier, wherein the AV peptoid is a peptide comprising AX1, wherein X1 is V, I or L, or a peptide mimetic thereof, which inhibits the activity of an Inhibitor of Apoptosis protein (IAP) as measured by IAP binding, procaspase-3 activation or promotion of apoptosis.Type: GrantFiled: August 23, 2000Date of Patent: August 19, 2003Assignee: Board of Regents, The University of Texas SystemInventors: Xiaodong Wang, Chunying Du
-
Patent number: 6599502Abstract: The invention provides methods and compositions relating to intracellular delivering of agents to eukaryotic cells. The compositions include microbial delivery vehicles such as nonvirulent bacteria comprising a first gene encoding a nonsecreted foreign cytolysin operably linked to a heterologous promoter and a second gene encoding a different foreign agent. The foreign agent may be a nucleic acid or protein, and is frequently bioactive in and therapeutic to the target eukaryote. In addition, the invention provides eukaryotic cells comprising the subject nonvirulent bacteria and nonhuman eukaryotic host organisms comprising such cells.Type: GrantFiled: September 7, 2001Date of Patent: July 29, 2003Assignee: The Regents of the University of CaliforniaInventors: Daniel A. Portnoy, Darren E. Higgins
-
Patent number: 6583277Abstract: The invention provides methods and compositions relating to semaphorin K1 (sema K1) polypeptides which regulate cellular guidance and physiology, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed sema K1 encoding nucleic acids or purified from human cells. The invention provides isolated sema K1 hybridization probes and primers capable of specifically hybridizing with the disclosed sema K1 genes, sema K1-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.Type: GrantFiled: January 26, 2001Date of Patent: June 24, 2003Assignee: Exelixis, Inc.Inventors: Yuling Luo, Xiaomei Xu
-
Patent number: 6582936Abstract: Nucleic acids are made by converting a primed single-stranded DNA to a double-stranded DNA by a method comprising the step contacting the single-stranded DNA with a DNA polymerase having 5′ exonuclease activity under conditions whereby the DNA polymerase converts the-single stranded DNA to the double-stranded DNA, wherein the single-stranded DNA is primed with oligonucleotide primer comprising a sequence complementary to the 3′ end of the single-stranded DNA, and at least one of the 5′ end of the primer and the single-stranded DNA comprises an RNA polymerase promoter joined to an upstream (5′) flanking moiety which protects the promoter from the 5′ exonuclease activity of the DNA polymerase.Type: GrantFiled: May 8, 2000Date of Patent: June 24, 2003Assignee: The Regents of the University of CaliforniaInventors: Tito Serafini, Percy Luu, John Ngai, David Lin
-
Patent number: 6582664Abstract: The invention provides multichannel pipette heads and autopipettors for loading, measuring, transporting and dispensing, particularly from one micro-plate to another. An exemplary multichannel pipette head comprises a pump housing, pistons, a drive plate, an aspiration drive and bearing rails, wherein the pump housing comprises chambers adapted to receive the pistons, the pistons each comprise a shaft, the drive plate retains the pistons and translocates the piston shafts through the chambers, the aspiration drive translocates the drive plate along the bearing rails which pass through the drive plate and attach to the pump housing.Type: GrantFiled: May 29, 2002Date of Patent: June 24, 2003Assignee: Incyte Genomics, Inc.Inventors: JoeBen Bevirt, Josh Guyot
-
Patent number: 6576444Abstract: The invention provides methods and compositions relating to a novel kinase, IRAK3. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IRAK3 encoding nucleic acids or purified from human cells. The invention provides isolated IRAK3 hybridization probes and primers capable of specifically hybridizing with the disclosed IRAK3 genes, IRAK3-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.Type: GrantFiled: May 22, 2001Date of Patent: June 10, 2003Assignee: Tularik Inc.Inventor: Zhaodan Cao
-
Patent number: 6576816Abstract: The invention provides methods and compositions for heavy metal phytoremediation, including plants which are genetically engineered to overexpress glutamylcysteine synthetase (ECS) and thereby provide enhanced heavy metal accumulation. In various embodiments, the plants comprise a gene encoding ECS operably linked to a heterologous promoter, the plant is a member of the Brassicaceae family. In general, the methods comprise the steps of growing such plants in a medium such as soil or water comprising a heavy metal, under conditions wherein ECS is overexpressed, whereby the plant provides enhanced accumulation of the heavy metal, whereby the heavy metal content of the medium is decreased.Type: GrantFiled: August 20, 2001Date of Patent: June 10, 2003Assignee: The Regents of the University of CaliforniaInventors: Norman Terry, Elizabeth Pilon-Smits, Yong Liang Zhu